Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis
Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis
复制标题
DOI：
10.1111/j.1365-2265.2008.03474.x
复制
发表时间：
2009-08-01
影响因子：
3.2
通讯作者：
Smit, J. W. A.
中科院分区：
文献类型：
--
作者：
Heemstra, K. A.;Hoftijzer, H. C.;Smit, J. W. A.
2型脱碘酶（D2）-Thr 92 Ala多态性在一些体外实验中与D2活性降低相关，但在其他实验中与D2活性降低无关。迄今为止，尚未在人类中观察到D2-Thr 92 Ala多态性与血清甲状腺激素水平之间的关联，但最近在甲状腺患者中的一项研究表明，Ala（92）等位基因纯合子患者需要更高的T4剂量才能实现TSH抑制。我们研究了D2-Thr 92 Ala多态性与甲状腺激素水平和T4剂量之间的关联，在分化型甲状腺癌（DTC）治疗的患者和桥本甲状腺炎治疗的患者组中。我们研究了154例接受TSH抑制性甲状腺激素替代治疗超过3年的DTC患者和141例接受至少6个月治疗的桥本甲状腺炎患者检测患者血清TSH、游离T4、T3和反T3水平，采用Taqman方法检测D2-Thr 92 Ala基因多态性。进行单因素回归分析，以确定T4剂量和D2-Thr 92 Ala多态性之间的关系，校正年龄，性别，BMI和血清TSH levels.ResultsBoth在DTC患者和桥本患者，血清甲状腺激素水平或T4剂量的D2-Thr 92 Ala多态性的存在下，没有观察到之间的关联。DTC患者根据TSH抑制程度的分类并没有改变这些result.ConclusionThe D2-Thr 92 Ala多态性与甲状腺激素水平或T4剂量治疗DTC或桥本甲状腺炎的患者。
P>ObjectiveThe type 2 deiodinase (D2)-Thr92Ala polymorphism has been associated with decreased D2 activity in some in vitro experiments but not in others. So far no association between the D2-Thr92Ala polymorphism and serum thyroid hormone levels has been observed in humans, but in a recent study in athyroid patients, it was suggested that patients homozygous for the Ala(92) allele needed higher T4 doses to achieve TSH suppression.We studied the association between the D2-Thr92Ala polymorphism with thyroid hormone levels and T4 dosage, in patients treated for differentiated thyroid carcinoma (DTC) and in a group of patients treated for Hashimoto thyroiditis.DesignCross-sectional study.PatientsWe studied 154 patients with DTC treated with TSH suppressive thyroid hormone replacement therapy for longer than 3 years and 141 patients with Hashimoto thyroiditis treated for at least 6 months with T4.MeasurementsIn all patients, serum levels of TSH, free T4, T3 and reverse T3 were measured and genotypes of the D2-Thr92Ala polymorphism were determined by Taqman assay. Univariate regression analysis was performed to determine the relation between T4 dosages and the D2-Thr92Ala polymorphism corrected for age, gender, BMI and serum TSH levels.ResultsBoth in DTC patients and Hashimoto patients, no association was observed between serum thyroid hormone levels or T4 dosages in presence of the D2-Thr92Ala polymorphism. Categorization of DTC patients according to degree of TSH suppression did not change these results.ConclusionThe D2-Thr92Ala polymorphism is not associated with thyroid hormone levels or T4 dose in patients treated for DTC or Hashimoto thyroiditis.